By: Andrew Dunn
A flashy collaboration between Sanofi, OpenAI and Formation Bio produced its first AI-powered tool, aiming to speed up the process of recruiting patients into clinical …
Andrew Dunn is a senior biopharma correspondent at Endpoints. He focuses on uncovering and explaining the future of the biotech and pharmaceutical industries, with particular interests in AI's emerging role in biotech, cell and gene therapy, and the intersection of money and medicine. Dunn's work has been featured in prominent outlets such as Yahoo News UK, Business Insider, and Bloomberg News, and he has appeared on networks including CNBC and MSNBC to discuss his insights.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Andrew Dunn's coverage primarily focuses on the healthcare and pharmaceutical industry, particularly on biotech, pharmaceutical companies, and research & development. He also covers business and finance aspects related to these sectors.
Given his high percentage of press releases in his coverage attributes, Andrew might be more inclined towards news directly from companies within the healthcare and pharmaceutical industries. Therefore, he may be interested in pitches that provide exclusive insights into new drug developments, breakthrough technologies or significant funding announcements within these sectors.
As Andrew often writes about CEOs and investments in the industry, experts who can offer unique perspectives on leadership strategies within biotech/pharmaceutical companies or trends in R&D investment could grab his attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .